Nanoly Bioscience

  • Home
  • Company
    • About Us
    • Leadership Team
    • Scientific Advisory Board
    • News & Awards
    • Careers
  • Technology
    • NanoShield
    • Data
    • Publications
  • Contact
  • Home
  • Company
    • About Us
    • Leadership Team
    • Scientific Advisory Board
    • News & Awards
    • Careers
  • Technology
    • NanoShield
    • Data
    • Publications
  • Contact

Our Team

We're proud of the talented people in our company. What we're building is incredibly difficult and would not be possible without working with the best team of scientists and operators. Nanoly is a venture-backed company.

We're always looking for the best and brightest people to join us. Visit our career page for more info.

Balaji Sridhar, MD, PhD, Co-Founder 
MD, University of Colorado Denver
PhD, Chemical Engineering, University of Colorado Boulder
BS Chemical-Biological Engineering, MIT

​Dr. Sridhar comes from more than 10 years of experience in biotechnology research including microscopy, polymer fabrication, and organic chemistry verification. Dr. Sridhar has worked as a researcher at MIT’s Langer Lab and for Chevron Corporation. Dr. Sridhar went on a medical mission to rural Africa and was inspired to co-found this company because of direct experience with issues in therapeutic accessibility secondary to cold chain failure. He completed his Ph.D. in renowned tissue engineer Kristi Anseth's Lab. 

Nanxi Liu, Co-Founder
BS Business Administration and BA Political Economy,
University of California, Berkeley
​
​Named Forbes 30 Under 30, Nanxi also co-founded and serves as CEO of Enplug, a leading digital signage software company. Nanxi previously worked in investment banking at Goldman Sachs and serves as an advisory board member of Covington Capital Management ($2 billion AUM). 
​John Janczy, PhD, ​Head of R&D
Postdoctoral Fellow, University of Colorado Anschutz Medical Campus
PhD Immunology, University of Iowa
BS Biology, Colorado Mesa University

​Dr. Janczy has over 6 years of experience in inflammation and immunology research. His work has focused primarily on pathogen recognition and the modulation of innate and adaptive immune responses.  Two of his most recent publications are:  “Immune complexes inhibit IL-1 secretion and inflammasome activation” (Journal of Immunology) and “Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation” (Immunity).

David Busha, PhD, Head of Commercial Development
PhD Molecular, Cellular & Developmental Biology,
MA Psychology/Neuroscience,

University of Colorado, Boulder 
BA Neuroscience, Macalester College

Dr. Busha has 9 years of biotech experience including as a core member at Five Prime Therapeutics where he developed several immuno oncology protein therapeutics. He has extensive experience designing novel protein molecules, recombinant fusion proteins, and bispecific antibodies.
​Nanoly Bioscience, Inc. 
Proudly located in Denver, Colorado
Copyright 2020

    ​Subscribe to our newsletter

Submit